Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$139.01

-8.99 (-6.07%)

20:10
04/20/17
04/20
20:10
04/20/17
20:10

Tesaro CEO responds to Zejula pricing questions, Endpoints News says

Tesaro CEO Lonnie Moulder has responded to questions surrounding the company's pricing of Zejula, saying that "if you read the FDA approved labeling you will see that 69% of patients are down-dosed, which means 31% continue on the 300mg daily starting dose and approximately 70% of the patients will receive either 200mg with a [Wholesale Acquisition Cost] of $9,833 or 100mg with a WAC of $4,917," reports Endpoints News, citing an email from Moulder. According to the report, the CEO added, "The down dosing occurs over the first 1-3 months which is not uncommon for oral anticancer agents as the physician 'dials in' the dose. The median dose and the most common dose were 200mg. Zejula is supplied as a 100mg capsule which means a patient takes either 1 or 2 or 3 capsules once daily based upon what they are prescribed." Reference Link

  • 30

    Jun

TSRO Tesaro
$139.01

-8.99 (-6.07%)

04/20/17
SBSH
04/20/17
NO CHANGE
Target $216
SBSH
Buy
Tesaro price target lowered to $216 from $232 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Tesaro to $216 to reflect the pricing of Zejula. After speaking to management, the analyst expects the net price to be around $9,000, lower than her $10,000 estimate. The price, however, could position the company well for a good launch and future competition, Karnauskas tells investors in a research note. She keeps a Buy rating on Tesaro.
04/20/17
LEER
04/20/17
NO CHANGE
Target $158
LEER
Market Perform
Tesaro price target lowered to $158 from $186 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Tesaro (TSRO) to $158 from $186 on valuation. The analyst notes that the company announced the availability and launch of Zejula as well as pricing of $14,750/month, a 7% premium to Clovis' (CLVS) Rubraca, but he estimates an average pricing of $10,350/month given the frequency of dose reductions. Fernandez reiterates a Market Perform rating on the shares pending the results of TOPACIO and ARIEL3.
04/20/17
RHCO
04/20/17
NO CHANGE
RHCO
Tesaro has no negative read through from AbbVie failure, says SunTrust
SunTrust analyst Peter Lawson says that there is "no impact" on Tesaro's (TSRO) niraparib from the failure of AbbVie's (ABBV) PARP inhibitor, veliparib, in triple negative breast cancer and lung cancer. The analyst believes that niraparib could be more effective than veliparib. Additionally, he notes that during its trial veliparib was used in combination with chemotherapy, while niraparib will be combined with Merck's (MRK) Keytruda for its trial. He thinks that the pairing with Keytruda will result in more effective treatment. The analyst keeps a $235 price target and a Buy rating on Tesaro.
04/20/17
COWN
04/20/17
NO CHANGE
COWN
Tesaro launch of Zejula reduces likelihood of a takeout, says Cowen
Cowen analyst Boris Peaker said Tesaro's launch of Zejula yesterday significantly reduces the likelihood of an "imminent" acquisition. The analyst believes the launch will be a disappointment for some investors that were holding the stock with an expectation for an imminent takeout. As previously discussed, Peaker did not expect a takeout at this stage given potentially significant competitor risk from Clovis's (CLVS) ARIEL3 trial expected to report results this summer. The analyst rates Tesaro a Market Perform with a $145 price target.

TODAY'S FREE FLY STORIES

CCL

Carnival

$68.56

-0.46 (-0.67%)

05:22
01/22/18
01/22
05:22
01/22/18
05:22
Periodicals
Woman falls to death from balcony aboard Carnival ship, Miami Herald reports »

A woman aboard the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$76.51

0.17 (0.22%)

, EQGP

EQT GP

$28.44

-0.19 (-0.66%)

05:21
01/22/18
01/22
05:21
01/22/18
05:21
Downgrade
EQT Midstream Partners, EQT GP, Rice Midstream rating change  »

EQT Midstream Partners…

EQM

EQT Midstream Partners

$76.51

0.17 (0.22%)

EQGP

EQT GP

$28.44

-0.19 (-0.66%)

RMP

Rice Midstream

$22.20

0.05 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQGP

EQT GP

$28.44

-0.19 (-0.66%)

05:19
01/22/18
01/22
05:19
01/22/18
05:19
Initiation
EQT GP initiated  »

EQT GP resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$56.03

-1.12 (-1.96%)

05:18
01/22/18
01/22
05:18
01/22/18
05:18
Initiation
EQT Corporation initiated  »

EQT Corporation resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANDX

Andeavor Logistics

$52.52

0.12 (0.23%)

05:16
01/22/18
01/22
05:16
01/22/18
05:16
Initiation
Andeavor Logistics initiated  »

Andeavor Logistics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

ANDV

Andeavor

$118.35

0.14 (0.12%)

05:15
01/22/18
01/22
05:15
01/22/18
05:15
Initiation
Andeavor initiated  »

Andeavor resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

IPAR

Inter Parfums

$47.80

0.9 (1.92%)

05:13
01/22/18
01/22
05:13
01/22/18
05:13
Downgrade
Inter Parfums rating change  »

Inter Parfums downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$38.77

-0.26 (-0.67%)

, STLD

Steel Dynamics

$46.42

0.16 (0.35%)

05:11
01/22/18
01/22
05:11
01/22/18
05:11
Upgrade
U.S. Steel, Steel Dynamics, Nucor, Commercial Metals rating change  »

U.S. Steel upgraded to…

X

U.S. Steel

$38.77

-0.26 (-0.67%)

STLD

Steel Dynamics

$46.42

0.16 (0.35%)

NUE

Nucor

$68.72

-0.1 (-0.15%)

CMC

Commercial Metals

$24.82

-0.27 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

  • 01

    Feb

ESPR

Esperion

$77.20

2.24 (2.99%)

05:06
01/22/18
01/22
05:06
01/22/18
05:06
Downgrade
Esperion rating change  »

Esperion downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$21.52

-0.58 (-2.62%)

05:02
01/22/18
01/22
05:02
01/22/18
05:02
Recommendations
Valeant analyst commentary  »

Valeant selloff Friday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 18

    Jun

  • 27

    Aug

WP

Worldpay

$78.73

-0.35 (-0.44%)

04:57
01/22/18
01/22
04:57
01/22/18
04:57
Recommendations
Worldpay analyst commentary  »

Worldpay price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$46.93

0.46 (0.99%)

, QGEN

Qiagen

$32.87

0.31 (0.95%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Recommendations
Quidel, Qiagen analyst commentary  »

Quidel price target…

QDEL

Quidel

$46.93

0.46 (0.99%)

QGEN

Qiagen

$32.87

0.31 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCO

Moody's

$159.18

1.6 (1.02%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Moody's management to meet with RBC Capital »

RBC Capital Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Feb

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

AKTX

Akari Therapeutics

$3.59

-0.01 (-0.28%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Akari Therapeutics management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

SANM

Sanmina

$35.45

0.5 (1.43%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Sanmina to hold a conference call »

Management holds an…Webcast Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

JAGX

Jaguar Health

$0.16

-0.0169 (-9.83%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Jaguar Health to hold a conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FE

FirstEnergy

$29.40

-0.16 (-0.54%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
FirstEnergy participates in a webcast with Wolfe Research »

Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
UBS REITs analyst holds an analyst/industry conference call »

REITs Analyst Yulico…

LLEX

Lilis Energy

$4.99

-0.12 (-2.35%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Lilis Energy management to meet with Seaport Global »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 24

    Jan

  • 30

    Jan

  • 31

    Jan

NAVG

Navigators

$49.65

0.4 (0.81%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Navigators management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 16

    Feb

PETS

PetMed Express

$53.24

2.67 (5.28%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Technical Analysis
Technical Earnings Preview: PetMed Express at life highs before news »

The stock is at life…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

December Chicago Fed…

BNED

Barnes & Noble Education

$7.70

0.25 (3.36%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Barnes & Noble Education management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.